Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor

References

• Liang X, Yang Q, Wu P, et al. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorg Chem. 2021;113:105011. doi:10.1016/j.bioorg.2021.105011
   PubMed Web of Science ®Google Scholar
• Li Y, Lv Y, Zhang C, et al. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy. Eur J Med Chem. 2023;257:115477. doi:10.1016/j.ejmech.2023.115477
   PubMed Web of Science ®Google Scholar
• Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med. 2018;18(Suppl 2):s41–s46. doi:10.7861/clinmedicine.18-2-s41
   PubMed Web of Science ®Google Scholar
• Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. Lung Cancer. Cancer Treatment and Research. 2016;170:25–46. doi:10.1007/978-3-319-40389-2_2
   Google Scholar
• Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1). doi:10.1186/s12943-018-0810-4
   PubMedGoogle Scholar
• Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nature Cancer. 2023;4(3):330–343. doi:10.1038/s43018-023-00515-0
   PubMedGoogle Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors inALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133. doi:10.1158/2159-8290.CD-16-0596
   PubMed Web of Science ®Google Scholar
• Wu W, Haderk F, Bivona T. Non-canonical thinking for targeting ALK-fusion Onco-proteins in lung cancer. Cancers (Basel). 2017;9(12):164. doi:10.3390/cancers9120164
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discovery. 2018;18(1):41–58. doi:10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Shankar E, Subramaniam V, Allimuthu D. Editorial: Adopting drug repurposing to overcome drug resistance in cancer. Front Cell Dev Biol. 2023;11:1191682. doi:10.3389/fcell.2023.1191682
   PubMed Web of Science ®Google Scholar
• Lee W-H, Loo C-Y, Ghadiri M, et al. The potential to treat lung cancer via inhalation of repurposed drugs. Adv Drug Delivery Rev. 2018;133:107–130. doi:10.1016/j.addr.2018.08.012
   PubMed Web of Science ®Google Scholar
• Gerber DE, Putnam WC, Fattah FJ, et al. Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer. Clin Cancer Res. 2020;26(22):6017–6027. doi:10.1158/1078-0432.CCR-20-1916
   PubMed Web of Science ®Google Scholar
• Chen B, Trang V, Lee A, et al. Posaconazole, a second-generation Triazole antifungal drug, inhibits the hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016;15(5):866–876. doi:10.1158/1535-7163.MCT-15-0729-T
   PubMed Web of Science ®Google Scholar
• Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42(4):623–631. doi:10.1124/dmd.113.056176
   PubMed Web of Science ®Google Scholar
• Robinson K, Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol. 2020;10:265. doi:10.3389/fonc.2020.00265
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. J Med Chem. 2014;57(11):4720–4744. doi:10.1021/jm500261q
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1). doi:10.1038/srep42717
   PubMedGoogle Scholar
• Bawadekji A, Imran M, Nayeem N. Posaconazole : a pharmaceutical review = : . . J North Basic Appl Sci. 2019;4(2):109–123.
   Google Scholar
• McLean AD, Chandler GS. Contracted Gaussian basis sets for molecular calculations. I. second row atoms, Z=11–18. J Chem Phys. 1980;72(10):5639–5648. doi:10.1063/1.438980
   Web of Science ®Google Scholar
• Krishnan R, Binkley JS, Seeger R, et al. Self-consistent molecular orbital methods. XX. A basis set for correlated wave functions. J Chem Phys. 1980;72(1):650–654. doi:10.1063/1.438955
   Web of Science ®Google Scholar
• Becke AD. Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys. 1993;98(7):5648–5652. doi:10.1063/1.464913
   Web of Science ®Google Scholar
• Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physical Review B. 1988;37(2):785–789. doi:10.1103/PhysRevB.37.785
   PubMed Web of Science ®Google Scholar
• Miehlich B, Savin A, Stoll H, et al. Results obtained with the correlation energy density functionals of becke and Lee, Yang and Parr. Chem Phys Lett. 1989;157(3):200–206. doi:10.1016/0009-2614(89)87234-3
   Web of Science ®Google Scholar
• Lee C-C, Kuo C-J, Ko T-P, et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and Peptidomimetic compounds. J Biol Chem. 2009;284(12):7646–7655. doi:10.1074/jbc.M807947200
   PubMed Web of Science ®Google Scholar
• Bowers KJ, Chow DE, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. ACM/IEEE SC 2006 Conference (SC'06)2006. p. 43-43.
   Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926–935. doi:10.1063/1.445869
   Web of Science ®Google Scholar
• Martyna GJ, Klein ML, Tuckerman M. Nosé–Hoover chains: the canonical ensemble via continuous dynamics. J Chem Phys. 1992;97(4):2635–2643. doi:10.1063/1.463940
   Web of Science ®Google Scholar
• Toukmaji AY, Board JA. Ewald summation techniques in perspective: a survey. Comput Phys Commun. 1996;95(2-3):73–92. doi:10.1016/0010-4655(96)00016-1
   Web of Science ®Google Scholar
• Kagami LP, das Neves GM, Timmers LFSM, et al. Geo-measures: a PyMOL plugin for protein structure ensembles analysis. Comput Biol Chem. 2020;87:107322. doi:10.1016/j.compbiolchem.2020.107322
   PubMed Web of Science ®Google Scholar
• Ghosh A, Mukerjee N, Sharma B, et al. Target specific inhibition of protein tyrosine kinase in conjunction with cancer and SARS-COV-2 by olive nutraceuticals. Front Pharmacol. 2022;12:812565. doi:10.3389/fphar.2021.812565
   PubMed Web of Science ®Google Scholar
• Al-Qubaisi M, Rozita R, Yeap S-K, et al. Selective cytotoxicity of Goniothalamin against Hepatoblastoma HepG2 Cells. Molecules. 2011;16(4):2944–2959. doi:10.3390/molecules16042944
   PubMed Web of Science ®Google Scholar
• Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439–449. doi:10.1038/sj.onc.1200849
   PubMed Web of Science ®Google Scholar
• Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(18):2175–2188. doi:10.1038/sj.onc.1201062
   PubMed Web of Science ®Google Scholar
• Jawarkar RD, Sharma P, Jain N, et al. QSAR, molecular docking, MD simulation and MMGBSA calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of ALK tyrosine kinase inhibitors as anticancer leads. Molecules. 2022: 27(15):4951. doi:10.3390/molecules27154951
   PubMed Web of Science ®Google Scholar
• Lorén CE, Scully A, Grabbe C, et al. Identification and characterization of DAlk: a novelDrosophila melanogasterRTK which drives ERK activationin vivo. Genes Cells. 2001;6(6):531–544. doi:10.1046/j.1365-2443.2001.00440.x
   PubMedGoogle Scholar
• Kong X, Pan P, Sun H, et al. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2019;62(24):10927–10954. doi:10.1021/acs.jmedchem.9b00446
   PubMed Web of Science ®Google Scholar
• Xu Z, Yang Z, Liu Y, et al. Halogen bond: its role beyond drug–target binding affinity for drug discovery and development. J Chem Inf Model. 2014;54(1):69–78. doi:10.1021/ci400539q
   PubMed Web of Science ®Google Scholar
• Bissantz C, Kuhn B, Stahl M. A medicinal chemist’s guide to molecular interactions. J Med Chem. 2010;53(14):5061–5084. doi:10.1021/jm100112j
   PubMed Web of Science ®Google Scholar
• Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm. 2011;2(5):349–355. doi:10.1039/C1MD00017A
   Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 2017;10(2):159–165. doi:10.1177/107327480301000207
   Google Scholar
• Thorn M, Finnstrom N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005;60(1):54–60. doi:10.1111/j.1365-2125.2005.02389.x
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1). doi:10.1186/s12935-015-0221-1
   PubMedGoogle Scholar